Expression of YAP1 delineates distinct subtypes of pulmonary large cell neuroendocrine carcinoma with divergent therapeutic implications.

ABSTRACT:

Background

Molecular subtyping [Type I (non-small cell lung carcinoma-like, NSCLC-like) and Type II (small cell lung carcinoma-like, SCLC-like)] and YAP1 expression analysis show promise for precision oncology in pulmonary large cell neuroendocrine carcinoma (LCNEC). However, their clinical utility and prognostic value remain unvalidated, and the aim of this study is to evaluate the disparity of clinicopathologic features, survival outcomes and treatment-relevant biomarkers between these two classifications.

Methods

We retrospectively analyzed 42 surgically resected pulmonary LCNECs. Using next-generation sequencing (NGS) and immunohistochemistry on archival specimens, we classified tumors by molecular subtype and YAP1 protein expression. Clinicopathological features, surviv

SUBMITTER: Zhu Y 

PROVIDER: S-EPMC12541834 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature